vs
Side-by-side financial comparison of Primoris Services Corp (PRIM) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $1.9B, roughly 2.0× Primoris Services Corp). On growth, Primoris Services Corp posted the faster year-over-year revenue change (6.7% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $121.1M). Over the past eight quarters, Primoris Services Corp's revenue compounded faster (14.7% CAGR vs 0.5%).
Primoris Services Corporation is a publicly traded specialty construction and infrastructure company based in the United States, with a particular focus on pipelines for natural gas, wastewater and water. As of 2014 it was a Fortune 1000 company.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
PRIM vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $3.7B |
| Net Profit | $51.7M | — |
| Gross Margin | 9.4% | 31.1% |
| Operating Margin | 4.2% | -5.2% |
| Net Margin | 2.8% | — |
| Revenue YoY | 6.7% | 5.0% |
| Net Profit YoY | -4.2% | — |
| EPS (diluted) | $0.94 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9B | $3.7B | ||
| Q3 25 | $2.2B | $3.7B | ||
| Q2 25 | $1.9B | $3.6B | ||
| Q1 25 | $1.6B | $3.2B | ||
| Q4 24 | $1.7B | $3.5B | ||
| Q3 24 | $1.6B | $3.7B | ||
| Q2 24 | $1.6B | $3.8B | ||
| Q1 24 | $1.4B | $3.7B |
| Q4 25 | $51.7M | — | ||
| Q3 25 | $94.6M | — | ||
| Q2 25 | $84.3M | — | ||
| Q1 25 | $44.2M | — | ||
| Q4 24 | $54.0M | — | ||
| Q3 24 | $58.4M | — | ||
| Q2 24 | $49.5M | — | ||
| Q1 24 | $18.9M | — |
| Q4 25 | 9.4% | 31.1% | ||
| Q3 25 | 10.8% | 36.6% | ||
| Q2 25 | 12.3% | 37.3% | ||
| Q1 25 | 10.4% | 35.8% | ||
| Q4 24 | 10.6% | 34.6% | ||
| Q3 24 | 12.0% | 39.0% | ||
| Q2 24 | 11.9% | 38.2% | ||
| Q1 24 | 9.4% | 41.2% |
| Q4 25 | 4.2% | -5.2% | ||
| Q3 25 | 6.3% | 4.8% | ||
| Q2 25 | 6.7% | 6.5% | ||
| Q1 25 | 4.3% | -88.9% | ||
| Q4 24 | 5.0% | -5.1% | ||
| Q3 24 | 6.0% | 6.0% | ||
| Q2 24 | 5.5% | -6.3% | ||
| Q1 24 | 3.1% | 5.6% |
| Q4 25 | 2.8% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | $0.94 | $-0.34 | ||
| Q3 25 | $1.73 | $-0.11 | ||
| Q2 25 | $1.54 | $0.00 | ||
| Q1 25 | $0.81 | $-2.55 | ||
| Q4 24 | $0.98 | $-0.43 | ||
| Q3 24 | $1.07 | $0.08 | ||
| Q2 24 | $0.91 | $-0.27 | ||
| Q1 24 | $0.35 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $535.5M | $1.3B |
| Total DebtLower is stronger | $469.9M | — |
| Stockholders' EquityBook value | $1.7B | $14.7B |
| Total Assets | $4.4B | $37.2B |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $535.5M | $1.3B | ||
| Q3 25 | $431.4M | $975.3M | ||
| Q2 25 | $390.3M | $566.4M | ||
| Q1 25 | $351.6M | $755.0M | ||
| Q4 24 | $455.8M | $734.8M | ||
| Q3 24 | $352.7M | $1.9B | ||
| Q2 24 | $207.4M | $917.2M | ||
| Q1 24 | $177.6M | $1.0B |
| Q4 25 | $469.9M | — | ||
| Q3 25 | $486.0M | — | ||
| Q2 25 | $603.1M | — | ||
| Q1 25 | $612.0M | — | ||
| Q4 24 | $734.8M | — | ||
| Q3 24 | $903.7M | — | ||
| Q2 24 | $933.0M | — | ||
| Q1 24 | $951.7M | — |
| Q4 25 | $1.7B | $14.7B | ||
| Q3 25 | $1.6B | $15.2B | ||
| Q2 25 | $1.5B | $15.6B | ||
| Q1 25 | $1.4B | $15.7B | ||
| Q4 24 | $1.4B | $18.6B | ||
| Q3 24 | $1.4B | $19.8B | ||
| Q2 24 | $1.3B | $19.5B | ||
| Q1 24 | $1.2B | $20.0B |
| Q4 25 | $4.4B | $37.2B | ||
| Q3 25 | $4.6B | $37.9B | ||
| Q2 25 | $4.5B | $38.4B | ||
| Q1 25 | $4.2B | $38.5B | ||
| Q4 24 | $4.2B | $41.5B | ||
| Q3 24 | $4.2B | $44.8B | ||
| Q2 24 | $4.0B | $45.3B | ||
| Q1 24 | $4.0B | $47.3B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.9M | $815.8M |
| Free Cash FlowOCF − Capex | $121.1M | $619.3M |
| FCF MarginFCF / Revenue | 6.5% | 16.8% |
| Capex IntensityCapex / Revenue | 1.2% | 5.3% |
| Cash ConversionOCF / Net Profit | 2.76× | — |
| TTM Free Cash FlowTrailing 4 quarters | $340.5M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.9M | $815.8M | ||
| Q3 25 | $182.9M | $744.9M | ||
| Q2 25 | $78.5M | $219.7M | ||
| Q1 25 | $66.2M | $535.5M | ||
| Q4 24 | $298.3M | $482.7M | ||
| Q3 24 | $222.5M | $826.5M | ||
| Q2 24 | $16.1M | $379.1M | ||
| Q1 24 | $-28.5M | $614.6M |
| Q4 25 | $121.1M | $619.3M | ||
| Q3 25 | $148.4M | $658.1M | ||
| Q2 25 | $45.3M | $166.8M | ||
| Q1 25 | $25.6M | $492.9M | ||
| Q4 24 | $270.0M | $342.3M | ||
| Q3 24 | $158.8M | $749.5M | ||
| Q2 24 | $-8.1M | $320.3M | ||
| Q1 24 | $-38.9M | $564.8M |
| Q4 25 | 6.5% | 16.8% | ||
| Q3 25 | 6.8% | 17.6% | ||
| Q2 25 | 2.4% | 4.7% | ||
| Q1 25 | 1.6% | 15.2% | ||
| Q4 24 | 15.5% | 9.7% | ||
| Q3 24 | 9.6% | 20.1% | ||
| Q2 24 | -0.5% | 8.5% | ||
| Q1 24 | -2.8% | 15.5% |
| Q4 25 | 1.2% | 5.3% | ||
| Q3 25 | 1.6% | 2.3% | ||
| Q2 25 | 1.8% | 1.5% | ||
| Q1 25 | 2.5% | 1.3% | ||
| Q4 24 | 1.6% | 4.0% | ||
| Q3 24 | 3.9% | 2.1% | ||
| Q2 24 | 1.5% | 1.6% | ||
| Q1 24 | 0.7% | 1.4% |
| Q4 25 | 2.76× | — | ||
| Q3 25 | 1.93× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 5.53× | — | ||
| Q3 24 | 3.81× | — | ||
| Q2 24 | 0.32× | — | ||
| Q1 24 | -1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
